Antibiotic Therapy Optimization in Special Populations
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 5510
Special Issue Editors
Interests: clinical pharmacokinetics; pharmacodynamics; clinical pharmacometrics; critical care; sepsis; obesity; drug therapy optimization
Interests: obstetric clinical pharmacology; pharmacometrics; drug metabolism; pediatric pharmacology; pharmacokinetics; pharmacodynamics; physiologically based pharmacokinetic modeling, drug-drug interactions, personalized medicine
Special Issue Information
Dear Colleagues,
In the era of antibiotic resistance, with few novel antimicrobial agents in the clinical pipeline, the importance of appropriate antibiotic use cannot be emphasized enough. One of the contributing factors to inappropriate antibiotic use is inadequate consideration of patient characteristics to design an individualized dosing regimen. Failure of the “one size fits all” theory to achieve optimal clinical outcomes is now evident, and the practice of medicine is moving toward individualized precision medicine. The primary reason for the failure of the “one size fits all” theory is substantial pharmacokinetic and pharmacodynamic variability among various patient populations.
Individualized precision antibiotic therapy is critical to optimize treatment outcomes because sufficient antimicrobial concentrations are imperative to achieve maximal killing activity, but excessive concentrations should be avoided in order to minimize antibiotic-associated toxicities. However, the design of optimal individualized antibiotic therapy regimen is particularly complicating for the patient populations whose gradual or acute pathophysiologic alterations substantially impact antimicrobial pharmacokinetics and pharmacodynamics. These patient populations are collectively called special populations and include critically ill patients, elderly populations, obese individuals, pediatric populations, immunocompromised patients, pregnant individuals, and patients with impaired organ functions. In these special populations, antibiotic clearance and volume of distribution are substantially different compared to general populations, requiring alternative antimicrobial dosing regimen. Additionally, change in their disease course over time affects intra-individual pharmacokinetic variability, resulting in continuous dosage adjustment in these patient populations. With the advancement of data computation technology and elaborate understanding of pathophysiology, scientific data contributing to the design of optimal antibiotic therapy are exponentially increasing.
In this Special Issue, scientific advances in designing optimal antibiotic therapy considering various patient characteristics will be discussed focusing on the aforementioned special patient populations. The multidisciplinary efforts in the field of antibiotic pharmacotherapy such as clinical pharmacokinetics and pharmacodynamics will provide insight for clinician scientists and healthcare professionals regarding the optimal antimicrobial therapy for special patient populations.
We look forward to your contributions to this important area of clinical practice and research.
Dr. Eun Kyoung Chung
Prof. Dr. Sara K. Quinney
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- clinical pharmacometrics
- PK/PD optimization of antibiotic therapy
- special populations
- critically ill patients
- elderly populations
- obesity
- immunocompromised patients
- pediatric populations
- pregnancy
- patients with impaired organ function
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
